A systematic review found insufficient evidence to determine what type of early volume expansion should be used in preterm infants (1) . The international guidelines 2000 conference for neonatal resuscitation recommended that emergency volume expansion be accomplished with an isotonic crystalloid solution or O-negative red blood cells (2).
In adults, hydroxyethyl starch (HES) has replaced albumin as the colloid administered for intravascular volume expansion in many indications (3) . Albumin is a blood product with a possible infectious risk, which costs substantially more than starch and has no proven benefit with respect to final outcome.
The various HES solutions on the market differ greatly in their pharmacologic properties and are available in two concentrations (high, 10%; and low, 6%).
The initial molecular weight of these solutions can be high (Ͼ400 kDa), medium (130 -200), or low (40 -70). The degree of hydroxyethyl substitution may be high (0.6 -0.7) or low (0.4 -0.5), and the same is true for the C2/C6 ratio (high, Ͼ8; low, Ͻ8) (3). Molecular weight determines colloidal activity, and the degree of substitution is the major determinant of circulating half-life. Hydrolysis is rapid with minimal substitution, and starch metabolism increases as the C2/C6 ratio decreases. Medium or low molecular weight HES are quickly split in vivo into smaller, more favorable, molecule sizes that result in faster renal elimination and fewer adverse effects on coagulation (3). Although medium molecular weight (mmw) HES can prolong activated partial thromboplastin time (aPTT) and induce a moderate decrease in plasma concentrations of von Willebrand factor, clinical studies have found no increased bleeding tendency after administration of mmw HES (4). The rate of anaphylactoid reactions is 0.058% for HES and 0.099% for albumin (5) . Some reports have suggested that HES could lead to adverse renal effects (6) , and the use of a slowly degradable mmw HES was found to be an independent risk factor for acute renal failure in severe sepsis (7) .
No HES side effects were reported in the three controlled trials performed to date in pediatrics (8 -10) , and a search procedure in Pubmed failed to turn up any data for newborns. Our assumption was that HES could replace human albumin in neonates. The renal function of newborns is remarkably immature. The glomerular filtration rate doubles from birth to 2 wks of life (from 5 to 10 mL·min Ϫ1 ·m Ϫ2 ) and reaches adult values only at about 2 yrs of life (70 mL·min Ϫ1 ·m Ϫ2 ) (11) . The main objective of our pilot study was to estimate the renal effects of HES in healthy newborns.
MATERIALS AND METHODS
A randomized, blinded study was designed to compare the effects of HES and albumin on creatininemia in neonates. Approval was obtained from the Ethics Committee of Nantes University Hospital, and both parents of each child gave their informed consent.
Infants eligible for inclusion were Ͻ28 days old (regardless of gestational age), without cardiac failure and in need of a central catheter for prolonged parenteral nutrition. In our unit, a plasma volume expander often is infused into these infants to facilitate peripheral insertion of a central catheter by filling up the peripheral veins. The criteria contraindi- 
Ϫ1 , hemostasis factors (II, V, VIIϩX) of Ͻ40%, and thrombopenia (platelet count of Ͻ100,000 mL Ϫ1 ). After parental consent, the neonates were allocated randomly to receive intravenous infusion at 10 mL·kg Ϫ1 of 5% albumin (Albu-
Creatininemia was measured before infusion (H0) and 6 hrs, 24 hrs, 48 hrs, and 7 days after infusion, with monitoring of diuresis. This dosage was performed by the rateblanked creatinine/Jaffe method (variance ϭ 0.95 mol·L Ϫ1 ), which eliminates bilirubin interference (12) in nonhemolyzed blood samples (hemolysis of fetal hemoglobin could lead to underestimation of creatininemia value). Coagulation was explored by measuring aPTT before and 6 hrs after infusion. The anaphylactoid reactions searched for during 6 hrs in both groups were respiratory disturbance, hypotension, and rash. Measurements of systemic pressure and heart rate were performed every 5 mins by using an automated oscillometric device (Critikon; Johnson & Johnson, Arlington, TX).
Statistical Analysis. The primary outcome measure under study was creatininemia. Our hypothesis was that HES should definitely not be used as a plasma expander in newborns if the increase in mean creatininemia exceeded 20 mol·L Ϫ1 . Thus, sample size was calculated to detect an increase in median creatininemia of Ͼ20 mol·L Ϫ1 between the two groups (with ␣ ϭ 0.05, ␤ ϭ 0.80, a unilateral formula, and with expected variance ϭ 420). Thirteen newborns were required in each group. The characteristics of the two groups were studied by using the Mann-Whitney test for unpaired nonparametric data. Creatininemia and mean arterial pressure were compared by using analysis for repeated measurements with group as one factor and time as second factor (general linear model procedure with analysis of variance). Data were analyzed with SPSS 10.0 computer software (SPSS, Chicago, IL). Values are presented as median (25th and 75th percentiles). The significance level was set at p Ͻ .05.
RESULTS
Twenty-six neonates (11 girls) were administered a 30-min infusion of 10 mL·kg Ϫ1 of a plasma volume expander and then equipped with a peripherally inserted central catheter for prolonged parenteral nutrition. Thirteen received 6% HES (HES group) and 13 others 5% albumin (albumin group). No catheter insertion failures occurred in either group.
Weight, gestational age, and postnatal age were similar in both groups (Table 1) , each of which included 11 preterm infants. Mean arterial pressure, heart rate, creatininemia, and aPTT were comparable before colloid infusion (Table 1) .
No differences were observed in creatininemia between the two groups at 6 hrs, 24 hrs, 48 hrs, and 7 days after plasma volume expansion (Fig. 1) . On the 7th day, creatininemia was 41 mol·L Ϫ1 (25th and 75th percentiles, 33 and 59) in the HES group vs. 43 (36 and 69) in the albumin group. As the observed variance of creatininemia was 420, the study detected an increase in creatininemia Ն20 mol·L Ϫ1 with a power of 80% and p Ͻ .05. Hourly diuresis in both groups showed a comparable course throughout a 24-hr period (Fig. 1) .
No differences in mean arterial pressure were observed between the two groups at H0, 30 mins, and 1 hr after plasma volume expansion (Fig. 1) . No bleeding duration of Ͼ3 mins occurred in either group after venous prick for catheter insertion. At 6 hrs, aPTT was 47 secs (42 and 59) in the HES group and 45 secs (42 and 58) in the albumin group (p ϭ .3). No anaphylactoid reactions occurred.
DISCUSSION
Plasma volume expansion with 10 mL·kg Ϫ1 of 6% HES 200/0.5 did not increase creatininemia in neonates without initial renal failure.
In newborns, plasma creatinine concentrations vary according to maternal creatinine concentration and gestational age and postnatal age (13) . The plasma creatinine concentration is elevated at birth (almost identical to maternal concentration) and decreases concomitantly with the rapid increase in glomerular filtration rate during the first postnatal weeks. In preterm infant, plasma creatinine concentrations remain high because of backflow of creatinine across leaky immature tubular and vascular structures. Paradoxically, concentrations are higher for a long time as the infant is more premature. In this study, both groups had comparable baseline creatininemia, gestational age, and postnatal age. Creatininemia developed similarly in both groups, with no differences in diuresis. Therefore, renal effects were no more severe with the HES we infused than with albumin. Our study did not explore coagulation patterns extensively, and factor VIII was not measured in order to save neonate blood. However, no differences in aPTT and no tendency to increased bleeding were observed. The fact that newborns and preterms have increased von Willebrand factor concentration may be an important consideration (14) .
Six percent HES 200/0.5, a lowconcentration (6%), medium molecular weight (200 kDa) HES, was chosen to treat newborn and premature infants because it is iso-oncotic for plasma and has a low degree of hydroxyethyl substitution (0.5), thereby allowing faster metabolism. Rapidly degradable mmw HES also has fewer adverse effects on coagulation than high molecular weight HES or slowly degradable mmw HES (3).
This study has several limitations: A single dose of HES was considered in healthy newborns, and too few infants were investigated to detect anaphylactoid reactions. However, the data reported suggest that 10 mL·kg Ϫ1 of HES, administered to facilitate intravenous insertion, has no apparent deleterious effects on newborns. 
